Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

U.S. government earmarks $1.6 billion to battle opioid crisis and overdose epidemic

By Brian Buntz | September 23, 2022

Opioids

[Photo by Karolina Grabowska from Pexels]

The U.S. Department of Health and Human Services (HHS) has awarded more than $1.6 billion as a part of an initiative to battle the drug overdose epidemic.

SAMHSA’s State Opioid Response (SOR), Tribal Opioid Response (TOR) grant programs and Health Resources and Services Administration (HRSA)’s rural communities opioid response programs will lead the new initiative.

The government plan will expand access to the opioid mu receptor antagonist naloxone, and improve access to opioid treatment programs. It also includes provisions to reduce abuse of stimulants such as cocaine and methamphetamine that contribute to the overdose epidemic.

The government initiative will also provide funding for law enforcement in high-intensity drug trafficking areas.

Drug-involved overdose deaths have surged in recent years, according to federal statistics.

In 2020, there were almost 92,000 drug-involved overdose deaths. More than 107,000 Americans died from drug overdoses in 2021. For comparison, there were 52,404 in 2015.

Drugs contributing to the deaths include fentanyl and fentanyl analogs, methamphetamine, and cocaine.

Nitazenes, an extremely potent class of synthetic opioids, have also seen growing use in the U.S.

“Providing access to evidence-based, person-centered care is a central part of HHS’ strategy for ending the overdose crisis,” said HHS Secretary Xavier Becerra, in a news release. “Through these grants, we are investing in evidence-based supports and services for individuals, families and communities on the road to recovery. Through these grants, we are investing in hope.”

The White House’s budget request for fiscal year 2023 calls for further increases for National Drug Control Program agencies. In all, President Buden’s budget request allocates $42.5 billion for the agencies. The sum represents a $3.2 billion increase over the prior year.

The FDA is currently conducting a review of the use of prescription opioids.

In August, FDA Commissioner Dr. Robert Califf announced that it had created a new overdose prevention framework.

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at [email protected].

Comments

  1. Mike Kolf says

    September 27, 2022 at 3:31 pm

    Access to naloxone is good. There is a lot of drug coming in through our open southern border, much of it is originally from China. The border and China need to be dealt with.

    Reply

Tell Us What You Think! Cancel reply

Related Articles Read More >

This is the logo of Johnson & Johnson.
Johnson & Johnson announces new North Carolina pharma plant
Samsung Biologics GSK Rockville Maryland plant (1)
Samsung Biologics acquires GSK manufacturing site
Fujifilm logo
Chitose, Fujifilm Biosciences partner on biopharma manufacturing
This is the logo of Novartis.
Novartis breaks ground on North Carolina facility
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2026 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE